Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone ER for Prevention of Relapse in Schizophrenia
NCT01662310Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2011
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Paliperidone ER with Placebo (2 arms). Primary endpoint: Median Time to Relapse. Started Jun 2011; status: completed.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01662310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01662310.